A genomic study of 149 systemic anaplastic large cell lymphoma cases identifies distinct survival-relevant mutational landscapes between ALK-positive and ALK-negative subtypes. The analysis highlights TP53 alterations as key markers of adverse clinical outcomes. By separating ALK-defined biology at the mutation level, the work supports subtype-tailored prognostic biomarker development rather than relying on broad clinicopathologic grouping alone. The dataset does not specify therapeutic implications beyond risk stratification.